Calculus makes exits in Genedrive and Yourgene

  • Realisation in Genedrive achieved an average of 2x return for investors, while Yourgene netted an average of 1.64x return
  • Both companies are listed on AIM, and benefitted from significant growth in the share price during the current pandemic, by refocusing their resources to COVID-19 testing

Genedrive is a molecular diagnostics company developing and commercialising a low cost, rapid, simple to use and robust point of need molecular diagnostics platform. With the global shift of healthcare turning to the testing and treatment of COVID-19, the company refocused part of its resources to the development of two SARS-COV-2 tests. This combined with a long-term supply agreement with the US Dept of Defense for the company’s biohazard test, and progress on its antibiotic induced hearing loss test for neo-natals, resulted in a significant increase in the Genedrive share price.

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. Yourgene offers COVID-19 testing as the company has developed and manufactured the Clarigene® SARS-CoV-2 test in their laboratory. This testing service is available through their network of partners to provide workplace and private testing to enable people to get back to work, school and to travel.

Calculus still have a holding in both companies which we will look to sell, markets permitting.